Fabio Eisfeld: Plasma-derived Drugs Cannot Be Produced Synthetically, They Depend Entirely On The Generosity of Healthy Donors
Fabio Eisfeld, HR Manager Latam at Grifols, shared on LinkedIn:
”Last week, we celebrated International Plasma Awareness Week (IPAW2025 ), and Grifols employees in Latin America actively participated!
Here are photos of colleagues dressed in yellow to contribute to this important moment.
Created by the Plasma Protein Therapeutics Association (PPTA), IPAW is dedicated to highlighting the value of human plasma, recognizing the generosity of donors, and promoting understanding of plasma-derived therapies.
Plasma-derived drugs cannot be produced synthetically; they depend entirely on the generosity of healthy donors.
These donations provide essential proteins, which often represent the only therapy available to patients.
Millions of people around the world, both those suffering from rare and chronic diseases and those facing trauma or medical emergencies, rely on plasma-derived therapies.
We remain firm in our goal: to produce and deliver medicines that provide quality of life to our patients!”
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies